Allon’s intellectual property portfolio strengthened with additional U.S. patent

05-Dec-2011 - Canada

Allon Therapeutics Inc. announced that it has been granted a United States patent covering the use of Allon’s drug candidates, including its lead product davunetide, and other pipeline products, for the treatment of laser induced retinal damage. This new patent strengthens Allon’s intellectual property estate which includes 15 patent families, 60 issued patents and over 30 pending applications worldwide.

This patent relates to findings recently published in Acta Ophthalmologica which reported that davunetide has neuroprotective effects in an animal model of retinal laser injury. The results suggest the potential of davunetide as a treatment for retinal damage following retinal laser photocoagulation or other types of ophthalmic laser surgeries.

Dr. Alistair Stewart, Allon’s Vice President of Commercial Research, said this new U.S. patent is illustrative of the Company’s success in generating broad patent coverage around Allon’s novel molecules and potential applications. “Davunetide has consistently shown its broad protective effects in neurodegenerative diseases, both in preclinical and human studies”, said Stewart. “This recent study indicates davunetide has potential in other types of brain disease and injury where neuroprotection can have a positive impact.”

Allon’s patent portfolio also includes issued patents and pending patent applications that provide protection around davunetide and its technology platform for treatment of neurodegenerative diseases, including progressive supranuclear palsy (PSP), Alzheimer’s disease, and Parkinson’s disease.

https://www.bionity.com/en/news/135479/allons-intellectual-property-portfolio-strengthened-with-additional-u-s-patent.html